Anbio Biotechnology [NNNN] vs Avantor [AVTR] Detailed Stock Comparison
Anbio Biotechnology
NASDAQ
Loading...
Avantor
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Anbio Biotechnology wins in 5 metrics, Avantor wins in 10 metrics, with 0 ties. Avantor appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Anbio Biotechnology | Avantor | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 713.33 | 11.25 | Avantor |
| Price-to-Book Ratio | 105.16 | 1.23 | Avantor |
| Debt-to-Equity Ratio | 0.00 | 67.49 | Anbio Biotechnology |
| PEG Ratio | N/A | 10.05 | N/A |
| EV/EBITDA | 793.57 | 10.63 | Avantor |
| Profit Margin (TTM) | 28.99% | 10.31% | Anbio Biotechnology |
| Operating Margin (TTM) | -68.64% | 7.65% | Avantor |
| EBITDA Margin (TTM) | N/A | 7.65% | N/A |
| Return on Equity | 14.83% | 11.73% | Anbio Biotechnology |
| Return on Assets (TTM) | 7.18% | 3.33% | Anbio Biotechnology |
| Free Cash Flow (TTM) | $2.08M | $692.00M | Avantor |
| 1-Year Return | 641.77% | -55.63% | Anbio Biotechnology |
| Price-to-Sales Ratio (TTM) | 229.51 | 1.16 | Avantor |
| Enterprise Value | $1.87B | $11.53B | Avantor |
| EV/Revenue Ratio | 228.07 | 1.73 | Avantor |
| Gross Profit Margin (TTM) | N/A | 33.82% | N/A |
| Revenue per Share (TTM) | $0 | $10 | Avantor |
| Earnings per Share (Diluted) | $0.06 | $1.01 | Avantor |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Anbio Biotechnology vs Avantor Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Anbio Biotechnology | -3.97% | -15.45% | 36.13% | 580.45% | 641.77% | 641.77% |
| Avantor | -15.48% | -20.06% | -18.39% | -12.35% | -48.06% | -46.42% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Anbio Biotechnology | 641.77% | 641.77% | 641.77% | 641.77% | 641.77% | 641.77% |
| Avantor | -55.63% | -60.21% | -47.58% | -21.66% | -21.66% | -21.66% |
Performance & Financial Health Analysis: Anbio Biotechnology vs Avantor
| Metric | NNNN | AVTR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.88B | $7.74B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 126,990 | 18,586,930 |
| 90 Day Avg. Volume | 204,380 | 13,623,450 |
| Last Close | $42.80 | $11.36 |
| 52 Week Range | $5.18 - $55.65 | $10.82 - $27.83 |
| % from 52W High | -23.09% | -59.18% |
| All-Time High | $55.65 (Jul 15, 2025) | $44.37 (Sep 20, 2021) |
| % from All-Time High | -23.09% | -74.40% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.36% | -0.01% |
| Quarterly Earnings Growth | N/A | -0.30% |
| Financial Health | ||
| Profit Margin (TTM) | 0.29% | 0.10% |
| Operating Margin (TTM) | -0.69% | 0.08% |
| Return on Equity (TTM) | 0.15% | 0.12% |
| Debt to Equity (MRQ) | 0.00 | 67.49 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.41 | $9.22 |
| Cash per Share (MRQ) | $0.27 | $0.66 |
| Operating Cash Flow (TTM) | $2.08M | $681.80M |
| Levered Free Cash Flow (TTM) | $1.27M | $685.76M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Anbio Biotechnology vs Avantor
| Metric | NNNN | AVTR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 713.33 | 11.25 |
| Forward P/E | N/A | 10.05 |
| PEG Ratio | N/A | 10.05 |
| Price to Sales (TTM) | 229.51 | 1.16 |
| Price to Book (MRQ) | 105.16 | 1.23 |
| Market Capitalization | ||
| Market Capitalization | $1.88B | $7.74B |
| Enterprise Value | $1.87B | $11.53B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 228.07 | 1.73 |
| Enterprise to EBITDA | 793.57 | 10.63 |
| Risk & Other Metrics | ||
| Beta | N/A | N/A |
| Book Value per Share (MRQ) | $0.41 | $9.22 |
Financial Statements Comparison: Anbio Biotechnology vs Avantor
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NNNN | AVTR |
|---|---|---|
| Revenue/Sales | N/A | $1.58B |
| Cost of Goods Sold | N/A | $1.05B |
| Gross Profit | N/A | $534.90M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | $147.40M |
| EBITDA | N/A | $230.80M |
| Pre-Tax Income | N/A | $85.70M |
| Income Tax | N/A | $21.20M |
| Net Income (Profit) | N/A | $64.50M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NNNN | AVTR |
|---|---|---|
| Cash & Equivalents | $11.76M | $315.70M |
| Total Current Assets | $18.53M | $2.28B |
| Total Current Liabilities | $1.73M | $2.03B |
| Long-Term Debt | N/A | $3.28B |
| Total Shareholders Equity | $17.19M | $6.10B |
| Retained Earnings | $17.17M | $2.27B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NNNN | AVTR |
|---|---|---|
| Operating Cash Flow | N/A | $86.60M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $81.30M |
| Debt Repayment | N/A | $-31.30M |
| Common Stock Repurchase | N/A | $-4.90M |
Short Interest & Institutional Ownership Analysis
| Metric | NNNN | AVTR |
|---|---|---|
| Shares Short | 175,289 | 40.07M |
| Short Ratio | 0.74 | 3.41 |
| Short % of Float | 0.00% | 0.08% |
| Average Daily Volume (10 Day) | 126,990 | 18,586,930 |
| Average Daily Volume (90 Day) | 204,380 | 13,623,450 |
| Shares Outstanding | 43.89M | 680.80M |
| Float Shares | 39.69M | 663.97M |
| % Held by Insiders | 0.05% | 0.01% |
| % Held by Institutions | 0.05% | 1.02% |
Dividend Analysis & Yield Comparison: Anbio Biotechnology vs Avantor
| Metric | NNNN | AVTR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |